Objectives: To determine efficacy based on pooled data from 2 pivotal Phase 3 studies of tofacitinib in patients (pts) with active PsA. Methods: Data were pooled from 2 placebo (PBO)-controlled, double-blind, multicentre, global Phase 3 studies (OPAL Broaden [N=422; 12 months; NCT01877668]; OPAL Beyond [N=394; 6 months; NCT01882439]). Pts had active PsA and either inadequate response (IR) to ≥1 conventional synthetic disease-modifying antirheumatic drug (csDMARD) and were tumour necrosis factor inhibitor (TNFi)-naïve (OPAL Broaden), or had IR to ≥1 TNFi (OPAL Beyond). Pts were randomised to tofacitinib 5 mg twice daily (BID), 10 mg BID, adalimumab 40 mg subcutaneous injection once every 2 weeks (OPAL Broaden only) or PBO, in addition to a single, stable background csDMARD. PBO pts advanced to tofacitinib 5 mg or 10 mg BID at Month (M)3. Endpoints included ACR20/50/70 response rates (≥20%, ≥50% and ≥70% improvement), change from baseline ( ) in HAQ-DI (Health Assessment Questionnaire-Disability Index), HAQ-DI response (decrease from baseline [BL] of ≥0.35), PASI75 (≥75% improvement from BL in Psoriasis Area and Severity Index), LEI (Leeds Enthesitis Index) and enthesitis absence, DSS (Dactylitis Severity Score) and dactylitis absence and DLQI (Dermatology Life Quality Index). Pooled data only included tofacitinib 5 mg and 10 mg BID (to M6) and PBO (to M3). Significance was declared for p≤0.05 without correction for multiplicity. Results: For pooled data, pts were predominantly white (94.2%) and female (55.4%) with ≥5 peripheral swollen or tender joints (98.0%), enthesitis (LEI>0; 67.5%), dactylitis (DSS>0; 52.5%), psoriatic body surface area ≥3% (67.7%) and CRP levels above the upper limit of normal (>2.87 mg/L; 62.5%) at BL. Mean age was 49.1 years and PsA duration was 8.0 years. Significant improvements vs PBO at M3 were observed for peripheral arthritis and physical function endpoints for tofacitinib 5 mg and 10 mg BID: ACR20, ACR50, ACR70, HAQ-DI (least squares mean [LSM]), and HAQ-DI response (Table 1 ). Significant improvements in psoriasis, enthesitis and dactylitis endpoints vs PBO were also observed for tofacitinib 5 mg and 10 mg BID at M3: PASI75, LEI, enthesitis absence based on LEI, DSS (LSM), dactylitis absence based on DSS and DLQI (Table 1) . Efficacy was maintained or further improved at M6.
Background: Secukinumab significantly improved the signs and symptoms of psoriatic arthritis (PsA) over 2 years (yrs) in the FUTURE 1 study. Objectives: To report efficacy and safety of secukinumab through 3 yrs in an extension of the FUTURE 1 study (NCT01892436). Methods: After 2-yr core trial, patients (pts) receiving secukinumab 150/75mg s.c. entered the 3-yr extension phase. Efficacy results at Week (Wk) 156 are presented for those pts originally randomised to secukinumab (n=308) and included ACR20/50/70, PASI 75, DAS28-CRP, SF-36 PCS, HAQ-DI, dactylitis and enthesitis. Multiple imputation was used for analysis of binary variables while continuous variables are reported as observed. Analyses by anti-TNF status (naïve/inadequate response) were prespecified and reported as observed. Safety analysis included all pts (n=587) who received ≥1 dose of secukinumab. Background: Achievement of minimal disease activity (MDA) may represent an objective target for treatment for patients with psoriatic arthritis (PsA).
1 A patient is considered to have achieved MDA when 5 of the following 7 criteria are met: tender joint count (TJC) ≤1, swollen joint count (SJC) ≤1, affected body surface area (BSA) ≤3%, patient pain VAS ≤15, patient global activity VAS ≤20, HAQ score ≤0.5 and tender entheseal points ≤1. Table 1 . Among responders, there were significant improvements in clinical characteristics and PROs such as mean TJC (3.4 vs 2.1 vs 0.6; P=0.004), SJC (2.5 vs 0.8 vs 0.5; P<0.0001), percentage of affected BSA (5.6% vs 2.4% vs 1.4%; P=0.03), patient pain (34.7 vs 26.1 vs 21.9; P=0.007) and HAQ scores (0.6 vs 0.4 vs 0.3; P=0.04); however, there were no significant changes over time for patient global assessment or enthesitis counts (P>0.05). Non-responders failed to have a significant improvement from baseline to the first and second FU visits in TJC, SJC, enthesitis, pain, patient global assessment and percentage of affected BSA (all P>0.05). Conclusions: Only 23% of patients achieved MDA on their index biologic at the second FU visit and were considered responders. Over time, responders showed significant improvements in TJC and SJC, percentage of affected BSA, patient pain and HAQ scores; these most likely contributed to achievement of MDA response. A treat-to-target approach may be considered given the low number of patients in MDA. 
